Status:
UNKNOWN
Platelets to Lymphocytes Ratio in Sepsis
Lead Sponsor:
Tanta University
Conditions:
Platelets to Lymphocytes Ratio Sepsis
Eligibility:
All Genders
21-65 years
Brief Summary
The aim of this study is to compare effectiveness of platelets to lymphocytes ratio (PLR) with procalcitonin as a predictor of sepsis outcome.
Detailed Description
Sepsis is a rapidly progressive, life-threatening disease. Accurate and expeditious assessment of sepsis is important for early administration of antibiotics and removal of the source of infection. I...
Eligibility Criteria
Inclusion
- Septic patients according to Third International Consensus Definitions for Sepsis
- with ICU stay more than 24 hours will be included.
Exclusion
- Pregnant and women in puerperium.
- Patients with active hemorrhage
- Patients with hematological diseases (including bone marrow diseases) and collagen diseases.
- Patients on corticosteroid therapy or immunosuppressive drugs.
- Patients who will need immediate surgical interventions.
- Acute cerebrovascular or coronary syndrome.
- Patients received blood or platelets transfusion before enrollment in the study.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05399225
Start Date
September 1 2022
End Date
June 1 2023
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta university of medicine
Tanta, Egypt, 31511